Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal

The U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio